Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Seventeen analysts give SRRK a consensus rating of Buy (12 Buy, 4 Strong Buy, 1 Sell) with an average 12‑month price target of $54.93.
• Shares opened at $50 with a market cap of $5.74 billion, 50‑day/200‑day moving averages of $46.11/$41.87, a negative PE of -14.58 and a 52‑week range of $27.07–$51.63; the company reported -$0.76 EPS for the quarter (beating estimates) and analysts forecast -2.42 EPS for the year.
• Insiders sold 54,143 shares worth $2.53 million in the last 90 days (insiders own 13.3%), while institutional investors hold roughly 91.08% of the stock.

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) has been given an average rating of "Buy" by the seventeen brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and four have given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $54.9286.

A number of equities research analysts have issued reports on SRRK shares. Piper Sandler increased their price objective on shares of Scholar Rock from $51.00 to $58.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 4th. Truist Financial boosted their target price on shares of Scholar Rock from $44.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, March 3rd. HC Wainwright reaffirmed a "buy" rating and set a $58.00 price target on shares of Scholar Rock in a report on Tuesday, March 3rd. Wedbush upped their price target on shares of Scholar Rock from $56.00 to $58.00 and gave the stock an "outperform" rating in a report on Wednesday, April 1st. Finally, JPMorgan Chase & Co. upped their price target on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an "overweight" rating in a report on Monday, March 16th.

Scholar Rock Price Performance

Shares of NASDAQ SRRK opened at $50.00 on Friday. The business has a fifty day moving average price of $46.11 and a two-hundred day moving average price of $41.87. The stock has a market capitalization of $5.74 billion, a PE ratio of -14.58 and a beta of 0.68. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.95 and a quick ratio of 6.95. Scholar Rock has a fifty-two week low of $27.07 and a fifty-two week high of $51.63.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.10. During the same period last year, the business earned ($0.64) EPS. As a group, equities analysts predict that Scholar Rock will post -2.42 earnings per share for the current fiscal year.

Insider Activity

In other news, General Counsel Junlin Ho sold 9,580 shares of the company's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $445,757.40. Following the completion of the sale, the general counsel owned 241,545 shares of the company's stock, valued at approximately $11,239,088.85. This represents a 3.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Mo Qatanani sold 8,484 shares of the company's stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $47.07, for a total transaction of $399,341.88. Following the sale, the insider directly owned 98,445 shares of the company's stock, valued at approximately $4,633,806.15. This trade represents a 7.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 54,143 shares of company stock worth $2,526,537. Insiders own 13.30% of the company's stock.

Institutional Trading of Scholar Rock

A number of institutional investors and hedge funds have recently made changes to their positions in the company. IFP Advisors Inc lifted its stake in Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company's stock valued at $27,000 after purchasing an additional 450 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Scholar Rock in the 4th quarter valued at approximately $30,000. Summit Securities Group LLC bought a new position in Scholar Rock in the 4th quarter valued at approximately $31,000. Ramirez Asset Management Inc. bought a new position in Scholar Rock in the 3rd quarter valued at approximately $37,000. Finally, EverSource Wealth Advisors LLC lifted its stake in Scholar Rock by 151.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company's stock valued at $38,000 after purchasing an additional 525 shares during the last quarter. Institutional investors own 91.08% of the company's stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company's research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock's approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company's lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.